相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
Paul E. Sax et al.
CLINICAL INFECTIOUS DISEASES (2020)
The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen
Lucia Taramasso et al.
AIDS (2020)
Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV
Aoife Lacey et al.
AIDS (2020)
Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study
Bernard Surial et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Kenneth H Mayer et al.
LANCET (2020)
A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017
Mario Gomez et al.
INFECTION (2019)
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
Willem D. F. Venter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2018 Recommendations of the International Antiviral Society-USA Panel
Michael S. Saag et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Effects of antiretroviral combination therapies F/TAF, E/C/F/TAF and R/F/TAF on insulin resistance in healthy volunteers: the TAF-IR Study
Christoph D. Spinner et al.
ANTIVIRAL THERAPY (2018)
Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide
Dzintars Gotham et al.
CURRENT OPINION IN HIV AND AIDS (2017)
Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options
A. A. Verhaegen et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2017)
Weight Gain: A Possible Side Effect of All Antiretrovirals
Lucia Taramasso et al.
OPEN FORUM INFECTIOUS DISEASES (2017)
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
Anthony Mills et al.
LANCET INFECTIOUS DISEASES (2016)
Weight Change After Antiretroviral Therapy and Mortality
Bianca Yuh et al.
CLINICAL INFECTIOUS DISEASES (2015)
The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial
Jose R. Santos et al.
CLINICAL INFECTIOUS DISEASES (2015)
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study
Anthony Mills et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
Paul E. Sax et al.
LANCET (2015)
Increasing obesity in treated female HIV patients from Sub-Saharan Africa: potential causes and possible targets for intervention
Claire L. McCormick et al.
FRONTIERS IN IMMUNOLOGY (2014)
Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study
Barbara Hasse et al.
OPEN FORUM INFECTIOUS DISEASES (2014)
Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202
Grace A. McComsey et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers
Paul A. Randell et al.
ANTIVIRAL THERAPY (2010)
Systematic Review and Meta-analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV-Infected Patients
Ryan D. Cooper et al.
CLINICAL INFECTIOUS DISEASES (2010)
Cohort Profile: The Swiss HIV Cohort Study
Franziska Schoeni-Affolter et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2010)
分享论文
